Brief: Cstone Pharmaceuticals Says Drug Met Endpoint Of Overall Survival In First-Line Treatment
19/01/2022 02:26
Jan 19 (Reuters) - CStone Pharmaceuticals 2616.HK :
* GEMSTONE-302 STUDY OF SUGEMALIMAB MET ENDPOINT OF OVERALL
SURVIVAL IN FIRST-LINE TREATMENT OF METASTATIC NSCLC PATIENTS
Further company coverage: 2616.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CStone Pharmaceuticals
See all newsBrief: CStone Pharmaceuticals Says CEO Purchases 496,000 Shares For Over HK$2.7 Million From Sept 17-22
Brief: CStone Pharmaceuticals Posts HY Loss Of Rmb252.3 Million
China's CStone Pharmaceuticals H1 revenue soars on drug sales
Brief: Cstone Pharmaceuticals Receives NMPA IND Approval For CS5007 In China
Brief: CStone Pharmaceuticals Says Directors And Senior Management Purchase 2.4 Million Shares In June 2026